Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HEXO HEXO	$0.71 +2.5%	$0.87	$0.66 ▼ $3.84	$31.24M	1.35	880,508 shs	305,500 shs
IMRX Immuneering	$3.96 -5.3%	$2.46	$1.00 ▼ $4.60	$150.42M	0.38	2.58 million shs	634,749 shs
IRWD Ironwood Pharmaceuticals	$0.74 +7.7%	$0.68	$0.53 ▼ $7.11	$111.17M	0.3	2.55 million shs	1.50 million shs
NKTX Nkarta	$1.83 +0.5%	$1.81	$1.31 ▼ $8.00	$129.14M	0.7	1.02 million shs	592,317 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HEXO HEXO	0.00%	0.00%	0.00%	0.00%	0.00%
IMRX Immuneering	-5.26%	-11.01%	+67.09%	+211.81%	+216.80%
IRWD Ironwood Pharmaceuticals	+7.67%	-8.03%	+10.40%	+2.03%	-89.25%
NKTX Nkarta	+0.55%	+1.10%	-3.17%	+1.10%	-77.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HEXO HEXO	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	3.2652 of 5 stars	3.3	2.0	0.0	0.0	2.7	5.0	0.6
IRWD Ironwood Pharmaceuticals	4.3457 of 5 stars	3.1	4.0	0.0	3.4	2.9	0.8	1.9
NKTX Nkarta	1.8108 of 5 stars	3.6	0.0	0.0	0.0	2.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HEXO HEXO	0.00	N/A	N/A	N/A
IMRX Immuneering	2.60	Moderate Buy	$13.25	234.60% Upside
IRWD Ironwood Pharmaceuticals	2.13	Hold	$4.78	546.66% Upside
NKTX Nkarta	3.13	Buy	$14.33	683.24% Upside

Current Analyst Ratings Breakdown

Latest HEXO, NKTX, IMRX, and IRWD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	IMRX Immuneering	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $10.00
6/18/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/18/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
6/5/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/7/2025	IMRX Immuneering	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $21.00
5/6/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HEXO HEXO	$146.20M	0.21	N/A	N/A	$2.44 per share	0.29
IMRX Immuneering	$320K	445.38	N/A	N/A	$1.33 per share	2.98
IRWD Ironwood Pharmaceuticals	$351.41M	0.34	$0.05 per share	13.89	($1.88) per share	-0.39
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HEXO HEXO	-$845.90M	-$5.21	N/A	N/A	N/A	-235.33%	-74.04%	-32.51%	N/A
IMRX Immuneering	-$61.04M	-$1.96	N/A	N/A	N/A	N/A	-119.22%	-99.22%	8/5/2025 (Estimated)
IRWD Ironwood Pharmaceuticals	$880K	-$0.20	N/A	2.96	N/A	-9.89%	-1.87%	-3.93%	8/6/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.51	N/A	N/A	N/A	N/A	-26.64%	-21.62%	8/12/2025 (Estimated)

Latest HEXO, NKTX, IMRX, and IRWD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	NKTX Nkarta	-$0.37	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	IMRX Immuneering	-$0.40	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/7/2025	Q1 2025	IRWD Ironwood Pharmaceuticals	-$0.05	-$0.14	-$0.09	-$0.23	$67.02 million	$41.14 million
5/5/2025	Q1 2025	IMRX Immuneering	-$0.41	-$0.42	-$0.01	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HEXO HEXO	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HEXO HEXO	0.01	0.41	0.24
IMRX Immuneering	N/A	7.48	7.48
IRWD Ironwood Pharmaceuticals	N/A	3.34	3.34
NKTX Nkarta	N/A	14.48	14.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HEXO HEXO	7.78%
IMRX Immuneering	67.65%
IRWD Ironwood Pharmaceuticals	N/A
NKTX Nkarta	80.54%

Insider Ownership

Company	Insider Ownership
HEXO HEXO	4.69%
IMRX Immuneering	22.90%
IRWD Ironwood Pharmaceuticals	12.70%
NKTX Nkarta	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HEXO HEXO	1,277	44.00 million	41.93 million	Optionable
IMRX Immuneering	60	35.99 million	27.75 million	Not Optionable
IRWD Ironwood Pharmaceuticals	220	161.82 million	141.27 million	Optionable
NKTX Nkarta	140	70.96 million	65.00 million	Optionable

HEXO, NKTX, IMRX, and IRWD Headlines

Recent News About These Companies

Peapod Lane Capital LLC Purchases New Stake in Nkarta, Inc. (NASDAQ:NKTX)

July 10, 2025 | marketbeat.com

Brokerages Set Nkarta, Inc. (NASDAQ:NKTX) PT at $14.33

July 8, 2025 | americanbankingnews.com

Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Buy" by Brokerages

July 5, 2025 | marketbeat.com

Nkarta (NASDAQ:NKTX) Stock Price Up 3% - Here's What Happened

July 2, 2025 | marketbeat.com

Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?

June 27, 2025 | uk.finance.yahoo.com

Nkarta, Inc. (NKTX) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Nkarta CMO David Shook Steps Down, Shawn Rose To Succeed

June 7, 2025 | nasdaq.com

Nkarta, Inc.: Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | finanznachrichten.de

Nkarta, Inc. Appoints Dr. Shawn Rose as Chief Medical Officer and Head of R&D

June 6, 2025 | quiverquant.comQ

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

June 6, 2025 | globenewswire.com

Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade

May 19, 2025 | zacks.com

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 15, 2025 | benzinga.com

William Blair Downgrades Nkarta (NKTX)

May 15, 2025 | msn.com

Nkarta, Inc.: Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 15, 2025 | finanznachrichten.de

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 14, 2025 | globenewswire.com

Nkarta (NKTX) Upgraded to Buy: Here's Why

April 14, 2025 | zacks.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Nkarta (NKTX) and Regeneron (REGN)

April 9, 2025 | markets.businessinsider.com

Nkarta to Participate in an April Investor Conference

April 1, 2025 | globenewswire.com

Nkarta: Betting On The Turnaround

March 31, 2025 | seekingalpha.com

Nkarta: Betting On The Turnaround

March 31, 2025 | seekingalpha.com

Nkarta: Grinding Lower, Trying To Find Support

March 31, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEXO, NKTX, IMRX, and IRWD Company Descriptions

HEXO NYSE:HEXO

HEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.

Immuneering NASDAQ:IMRX

$3.96 -0.22 (-5.26%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$3.92 -0.04 (-0.88%)

As of 07/16/2025 07:58 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.74 +0.05 (+7.67%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$0.74 0.00 (-0.37%)

As of 07/16/2025 06:40 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Nkarta NASDAQ:NKTX

$1.83 +0.01 (+0.55%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$1.82 -0.01 (-0.55%)

As of 07/16/2025 07:57 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time